Stewart Keri S, Kleinerman Eugenie S
Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Sarcoma. 2011;2011:165837. doi: 10.1155/2011/165837. Epub 2011 Jun 16.
Ewing's sarcoma accounts for a disproportionately high portion of the overall pediatric mortality rate compared to its rare incidence in the pediatric population. Little progress has been made since the introduction of traditional chemotherapies, and understanding the biology of the tumor is critical for developing new therapies. Ewing's sarcomas rely on a functional vascular supply, which is formed by a combination of angiogenesis and vasculogenesis. Recent insights into the molecular regulation of bone marrow (BM) cell participation in vascular development have identified VEGF, SDF-1α, and DLL4 as critical players in the vasculogenesis process. Clinical trials using vascular targeting agents, specifically targeting VEGF or DLL4, are underway.
与在儿科人群中罕见的发病率相比，尤因肉瘤在儿科总体死亡率中所占比例过高。自引入传统化疗以来进展甚微，了解肿瘤生物学对于开发新疗法至关重要。尤因肉瘤依赖功能性血管供应，这种供应由血管生成和血管发生共同形成。最近对骨髓（BM）细胞参与血管发育的分子调控的深入研究已确定血管内皮生长因子（VEGF）、基质细胞衍生因子-1α（SDF-1α）和三角洲样蛋白4（DLL4）是血管发生过程中的关键因子。使用血管靶向药物（特别是靶向VEGF或DLL4）的临床试验正在进行。
